162 related articles for article (PubMed ID: 22715200)
1. Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.
Nieman DH; Sutterland AL; Otten J; Becker HE; Drent ML; van der Gaag M; Birchwood M; de Haan L
BMJ Case Rep; 2011 Feb; 2011():. PubMed ID: 22715200
[TBL] [Abstract][Full Text] [Related]
2. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
3. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
Melkersson K; Hulting AL
Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):6-10. PubMed ID: 10738858
[TBL] [Abstract][Full Text] [Related]
4. Clozapine Treatment for Cabergoline-Induced Psychosis in a Patient With a Giant Prolactinoma.
Pérez-Esparza R; Rojas-Guerrero CA; Andino-Rios GG; Arias-Garro P; Ramírez-Bermúdez J; Portocarrero-Ortiz L
J Neuropsychiatry Clin Neurosci; 2017; 29(3):295-297. PubMed ID: 28238271
[No Abstract] [Full Text] [Related]
5. Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas.
Gupta P; Tundup T; Singh J; Deb KS; Verma R; Kumar N
Asian J Psychiatr; 2018 Jan; 31():129-132. PubMed ID: 29482124
[No Abstract] [Full Text] [Related]
6. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
7. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
8. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
11. Quinagolide in the management of prolactinoma.
Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
[TBL] [Abstract][Full Text] [Related]
12. Management of psychosis associated with a prolactinoma: case report and review of the literature.
Ali S; Miller KK; Freudenreich O
Psychosomatics; 2010; 51(5):370-6. PubMed ID: 20833935
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
14. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
16. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma-associated headache and dopamine agonist treatment.
Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
19. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
[TBL] [Abstract][Full Text] [Related]
20. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
